ASCENSIA DIABETES CARE LAUNCHES PATIENT ASSISTANCE PROGRAM TO PROVIDE BROADER ACCESS TO EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
Parsippany, United States
Ascensia Diabetes Care, a global diabetes company, announced it has introduced a Patient Assistance Program in the United States to reduce out-of-pocket costs associated with the Eversense® Continuous Glucose Monitoring (CGM) System.
Under the Program, which is available immediately, eligible patients starting or continuing with the Eversense CGM System will need to pay the first $100 of their out-of-pocket costs. Ascensia will then cover up to $300 of the remaining balance for each 90-day sensor. Any additional costs will be the system user’s responsibility. Overall, the Program has the potential to save eligible Eversense users up to $1,200 per year on their cumulative 90-day sensor out-of-pocket costs.
To find out more about the Program, potential and current Eversense users can go to www.ascensiadiabetes.com/eversense/patient-assistance-program-information and complete the eligibility form, after which the Ascensia team will reach out about next steps. They can also discuss with their health care provider.
Mary Puncochar, Head of Ascensia’s Region US, commented: “We hear from people living with diabetes and their healthcare providers how transformative the Eversense System can be in facilitating their diabetes management. People using the System appreciate how Eversense provides discretion with a removable transmitter, peace of mind through the on-body alerts, and the freedom that a 90-day sensor provides.
“Our fundamental goal at Ascensia is to simplify and improve the lives of people living with diabetes through technologies that facilitate better outcomes and reduce the burden of managing the condition. We therefore want to be able to offer Eversense to as many people as possible and we believe that over half of the people using insulin in the US could be eligible for our Patient Assistance Program. Our goal is to make Eversense more affordable and provide improved access to this unique and innovative diabetes management technology.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term implantable CGM sensor, the System is also the first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose. It can also be removed, recharged and re-attached to the skin without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
1. Christiansen, M.P. et al. (2009). A prospective multicenter evaluation of the accuracy and safety of an implanted continuous glucose sensor: the PRECISION study. Diabetes Technology & Therapeutic, 21(5), 231-237.doi:10.1089/dia.2019.0020.
2. Slattery D, Choudhary P. Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics 2017;19(2):55-61. DOI:10.1089.dia.2017.0051.
Notes for Editors
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® continuous glucose monitoring systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of the PHC Group and was established in 2016 through the sale of Bayer Diabetes Care to PHC Holdings (formerly Panasonic Healthcare). Ascensia products are sold in more than 125 countries. Ascensia has around 1,700 employees and operations in 31 countries.
For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
©2021 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
For more information, please contact:
Global Communications Manager
+41 76 432 46 25